Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Literature DB >> 3047665

Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Abstract

Etoposide (VP 16-213) and teniposide (VM 26) are semisynthetic epipodophyllotoxin derivatives active against a variety of tumours. The clinical efficacy has led to an increasing interest in these compounds. This review presents information on the mechanism of action, biochemical pharmacology, bioanalysis, metabolism and pharmacokinetics of etoposide and teniposide.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1988 PMID： 3047665 DOI： 10.1007/BF01959294

Source DB: PubMed Journal: Pharm Weekbl Sci ISSN： 0167-6555

84 in total

1. Analysis of 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) by high-pressure liquid chromatography.

Authors: L M Allen
Journal: J Pharm Sci Date: 1980-12 Impact factor: 3.534

2. High-performance liquid chromatography of etoposide in plasma and urine.

Authors: V J Harvey; S P Joel; A Johnston; M L Slevin
Journal: J Chromatogr Date: 1985-05-03

3. Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients.

Authors: C Rossi; M Zucchetti; C Sessa; R Urso; C Mangioni; M D'Incalci
Journal: Cancer Chemother Pharmacol Date: 1984 Impact factor: 3.333

4. EPEG, a new antineoplastic epipodophyllotoxin.

Authors: P J Creaven; L M Allen
Journal: Clin Pharmacol Ther Date: 1975-08 Impact factor: 6.875

5. Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors.

Authors: J A Sinkule; P Hutson; F A Hayes; E Etcubanas; W Evans
Journal: Cancer Res Date: 1984-07 Impact factor: 12.701

6. Pharmacokinetics of VP16-213 given by different administration methods.

Authors: M D'Incalci; P Farina; C Sessa; C Mangioni; V Conter; G Masera; M Rocchetti; M B Pisoni; E Piazza; M Beer; F Cavalli
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

7. Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide.

Authors: S Zimm; S M Cleary; W E Lucas; R J Weiss; M Markman; P A Andrews; M A Schiefer; S Kim; C Horton; S B Howell
Journal: Cancer Res Date: 1987-03-15 Impact factor: 12.701

8. High-dose etoposide for refractory malignancies: a phase I study.

Authors: P E Postmus; N H Mulder; D T Sleijfer; A F Meinesz; R Vriesendorp; E G de Vries
Journal: Cancer Treat Rep Date: 1984-12

9. High-performance liquid chromatography determination of 4'-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene beta-D-glucopyranoside) (VP 16-213) in human plasma.

Authors: P Farina; G Marzillo; M D'Incalci
Journal: J Chromatogr Date: 1981-01-02

10. Pharmacokinetics of teniposide in patients with ovarian cancer.

Authors: M D'Incalci; C Rossi; C Sessa; R Urso; M Zucchetti; P Farina; C Mangioni
Journal: Cancer Treat Rep Date: 1985-01

8 in total

1. A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II.

Authors: Gaik-Lean Chee; Jack C Yalowich; Andrew Bodner; Xing Wu; Brian B Hasinoff
Journal: Bioorg Med Chem Date: 2009-11-27 Impact factor: 3.641

2. Investigation and Expression of the Secoisolariciresinol Dehydrogenase Gene Involved in Podophyllotoxin Biosynthesis.

Authors: Sonja L B Arneaud; John R Porter
Journal: Mol Biotechnol Date: 2015-12 Impact factor: 2.695

3. Detection and identification ofPodophyllotoxin produced by cell cultures derived from podophyllum hexandrum royle.

Authors: W van Uden; N Pras; J F Visser; T M Malingré
Journal: Plant Cell Rep Date: 1989-03 Impact factor: 4.570

4. Increased podophyllotoxin production in Podophyllum hexandrum cell suspension cultures after feeding coniferyl alcohol as a β-cyclodextrin complex.

Authors: H J Woerdenbag; W van Uden; H W Frijlink; C F Lerk; N Pras; T M Malingré
Journal: Plant Cell Rep Date: 1990-07 Impact factor: 4.570

5. Production of podophyllotoxin from Podophyllum hexandrum: a potential natural product for clinically useful anticancer drugs.

Authors: A Giri; M Lakshmi Narasu
Journal: Cytotechnology Date: 2000-10 Impact factor: 2.058

6. Influence of ecological factors on the production of active substances in the anti-cancer plant Sinopodophyllum hexandrum (Royle) T.S. Ying.

Authors: Wei Liu; Jianjun Liu; Dongxue Yin; Xiaowen Zhao
Journal: PLoS One Date: 2015-04-15 Impact factor: 3.240

7. Genetic diversity and structure of Sinopodophyllum hexandrum (Royle) Ying in the Qinling Mountains, China.

Authors: Wei Liu; Dongxue Yin; Jianjun Liu; Na Li
Journal: PLoS One Date: 2014-10-15 Impact factor: 3.240

Review 8. Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment.

Authors: Joan Tymon-Rosario; Naomi N Adjei; Dana M Roque; Alessandro D Santin
Journal: Cancers (Basel) Date: 2021-12-12 Impact factor: 6.639

8 in total